AI in healthcare is entering a new chapter. Pat McGloin, shared with @cure345 why #ChatGPT5 could transform patient engagement, health literacy, and access – particularly if we keep the human in the loop. 🔗 https://t.co/UtAFjejdHk #DigitalHealth

🚨New Cure survey of 100+ healthcare CEOs + founders reveals: 87% remain optimistic about the future of biotech—despite funding dips + policy shifts. 📈 65% say access to capital is their top concern. 🔗 Read the full report: https://t.co/iPQDFuxKPM #Biotech #policyshifts

Researchers are excited about detecting tumor DNA circulating in patients' blood before other markers of cancer appear, and its potential to direct treatment early. Read my article on this trend in @cure345:

This morning, @xprize Executive Director, @j_n_justice and Cure CEO Seema Kumar kicked off the XPRIZE Healthspan Investor Summit. The event features semifinalist teams from the $101M XPRIZE Healthspan competition, 40 innovative organizations from around the globe, and leading

Register today:

🧠 FDA just cleared a wireless brain implant from @PrecisionNeuro_ in a new era for brain-computer interfaces (BCIs). 70+ clinical trials are testing BCI tech to restore movement, speech & mental health. 💥 $12B market incoming. 🔗 Read more: https://t.co/h0K0pdUKlo #Neurotech

@Sunbird_Bio is transforming brain disease detection with would could be a first-of-its-kind blood test that identifies neurodegeneration before clinical symptoms appear, for diseases such as Alzheimer’s, #ALS & Parkinson’s. Read More: https://t.co/0Kb8EtHI24 #braindiseases

🚨 New Trump-era tariffs are straining equipment costs for hospitals and research labs. 📊 Surveys show the fallout will be far-reaching. “The second wave of tariffs is no longer a theoretical threat—it’s a full-blown disruption,” says @blackbookpolls' Doug Brown. So, what’s next

Gene and cell therapies are 2x more likely to win FDA approval, but most still aren’t reaching patients. A new @Nature Reviews Drug Discovery study reveals why—cost, infrastructure & delivery gaps. Since 2017, 30+ therapies approved. Read More:

🚨 A new report from the bipartisan @NSCbiotech warns that the U.S. is falling behind China in biotech and calls for a $15B investment to protect our leadership in innovation, health, and security. 🧬 Read more by Cure writer @RS_Flinn : https://t.co/iXIQyQAmLn #Biotech

https://t.co/qt7ShYdMlC While biotech struggled, one category surged: AI-driven startups. @isomorphiclabs raised $600M—led by @thrivecapital with @GVteam & @Alphabet—to push AI drug discovery into the clinic. Read more from Cure writer @RS_Flinn, who explains how #AImoonshots are

https://t.co/0xogDRHYOQ "I'm deeply concerned by some of what has happened in recent weeks in terms of the cuts to science and research funding, particularly from my perspective in the #biomedical research domain. I fear that we are really undermining and dismantling critical and

https://t.co/fjqYjouGoO Washington DC advocates expressed concerns this week at the Power of X Summit about the Trump administration’s cuts to scientific research & their impact on the future of healthcare.

From Research to Reality: Action Plans Emerge as Cure’s “The Power of X” Summit Concludes https://t.co/lhl0EfoKKI

The Power of X Summit kicked off with Cure CEO @SeemaJJIC : Women’s health is the most significant untapped market opportunity—scientific innovation drives economic growth. WHAM CEO Carolee Lee shared new data making the business case for investing in women’s health. Later,

https://t.co/RfSqrjw1kg A novel IV treatment yields the first-of-its-kind genetic correction in living patients, signaling a new era in precision medicine. Read more about what scientists call a medical first from @BeamTx, who has successfully corrected a disease-causing genetic

🚨 One Week Left! 🚨 Join us at Power of X Summit March 24-25 in NYC! Excited to announce Viq Peervaz, SVP of Life Sciences & Healthcare @NYCEDC, will speak on scaling programs in NYC + how data can improve women’s health outcomes. Registered yet? https://t.co/kdH4c1gyY8

https://t.co/NeM22YruHR At @Jefferies’ Biotech Conference, John Crowley (CEO of @IAmBiotech), @jwhite_health & Raghav Aggarwal discussed how a President Trump policy shift could benefit #biotech. Industry leaders say there could be big moves on innovation & drug pricing reform.